GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » Selling, General, & Admin. Expense

Orphazyme AS (CHIX:ORPHAC) Selling, General, & Admin. Expense : kr391.40 Mil (TTM As of Jun. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Orphazyme AS's selling, general, & admin. expense for the three months ended in Jun. 2022 was kr27.30 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Jun. 2022 was kr391.40 Mil.


Orphazyme AS Selling, General, & Admin. Expense Historical Data

The historical data trend for Orphazyme AS's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS Selling, General, & Admin. Expense Chart

Orphazyme AS Annual Data
Trend Jun14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Selling, General, & Admin. Expense
Get a 7-Day Free Trial 44.18 75.33 114.01 342.20 421.44

Orphazyme AS Quarterly Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 78.58 263.62 57.34 364.10 27.30

Competitive Comparison of Orphazyme AS's Selling, General, & Admin. Expense

For the Biotechnology subindustry, Orphazyme AS's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orphazyme AS's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orphazyme AS's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Orphazyme AS's Selling, General, & Admin. Expense falls into.



Orphazyme AS Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was kr391.40 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Orphazyme AS  (CHIX:ORPHAc) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Orphazyme AS Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Orphazyme AS's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Orphazyme AS (CHIX:ORPHAC) Business Description

Industry
Comparable Companies
Traded in Other Exchanges
N/A
Address
Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200
Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS (CHIX:ORPHAC) Headlines

No Headlines